Managing Dyskinesia Through Continuous Infusion Therapy

Continuous infusion therapies are playing an increasingly important role in the evolving landscape of Parkinson disease management, particularly for patients experiencing motor fluctuations and troublesome dyskinesia. Traditional oral medications, while effective in early stages, often fail to provide consistent symptom control over time due to variable absorption and the progressive nature of the disease. Continuous dopaminergic stimulation through infusion therapies offers a more stable delivery of medication, helping to reduce “off” time and mitigate the risk of peak-dose dyskinesia that often accompanies intermittent dosing.

Clinical trials and real-world data have demonstrated that infusion therapies can significantly improve quality of life for individuals with Parkinson disease. These therapies, including both subcutaneous and intestinal infusion systems, have shown promising outcomes in reducing motor complications while allowing for more consistent control of both motor and nonmotor symptoms. As such, they are increasingly considered for patients who have not achieved satisfactory results with optimized oral regimens. Additionally, advancements in device technology and delivery methods continue to enhance the usability and tolerability of these treatments.

Looking ahead, the integration of infusion therapies into Parkinson care highlights the importance of individualized treatment planning. As the disease progresses, the goal remains to maintain functional independence and minimize complications. Future directions may include expanded indications for infusion therapies, earlier intervention strategies, and the development of novel agents designed for continuous delivery. Ongoing research is also exploring biomarkers and patient-specific factors that could guide the timing and selection of advanced therapies. As the therapeutic landscape broadens, infusion therapies are expected to remain a critical component in the long-term management of Parkinson disease and dyskinesia.